Status:

COMPLETED

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Lead Sponsor:

Pfizer

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18-70 years

Phase:

PHASE2

Brief Summary

This is a study to understand efficacy and safety of investigational agent (PF-04937319) compared to approved agent (glimepiride) in patients with diabetes on metformin

Eligibility Criteria

Inclusion

  • Age 18-70 yrs, male and females, with T2DM, on metformin alone or in combination with 1 other oral agent

Exclusion

  • Subjects with recent cardiovascular events, those with evidence of diabetic complications

Key Trial Info

Start Date :

February 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2013

Estimated Enrollment :

304 Patients enrolled

Trial Details

Trial ID

NCT01517373

Start Date

February 1 2012

End Date

January 1 2013

Last Update

January 31 2017

Active Locations (53)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (53 locations)

1

Sierra Clinical Research

Roseville, California, United States, 95661

2

California Research Foundation

San Diego, California, United States, 92103

3

Diablo Clinical Research, Inc.

Walnut Creek, California, United States, 94598

4

Meridien Research

Bradenton, Florida, United States, 34208

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin | DecenTrialz